Myozyme was first to market in 2006 for infantile-onset Pompe, with Lumizyme reaching the market four years later to treat late-onset Pompe in children aged over eight.

In 2006, HAS reviewed Myozyme for treatment of late-onset Pompe disease. HAS evaluated interim analysis from a non-comparative trial and observational data from an expanded access programme.